Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:SENS
CUSIPN/A
Phone+1-301-5157260
Debt
Debt-to-Equity Ratio0.76
Current Ratio2.93
Quick Ratio2.81
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$330,000.00
Price / Sales1,961.22
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-94.20
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-43,930,000.00
Net Margins-828.76%
Return on Equity-406.72%
Return on Assets-129.94%
Miscellaneous
Employees58
Outstanding Shares137,410,000
Senseonics (NYSEAMERICAN:SENS) Frequently Asked Questions
What is Senseonics' stock symbol?
Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."
How were Senseonics' earnings last quarter?
Senseonics Holdings (NYSEAMERICAN:SENS) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.04. The firm earned $2.90 million during the quarter, compared to the consensus estimate of $2.59 million. Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The company's revenue for the quarter was up 480.0% on a year-over-year basis. View Senseonics' Earnings History.
What price target have analysts set for SENS?
4 Wall Street analysts have issued 12-month target prices for Senseonics' stock. Their predictions range from $5.00 to $7.00. On average, they expect Senseonics' stock price to reach $5.75 in the next year. View Analyst Ratings for Senseonics.
What are Wall Street analysts saying about Senseonics stock?
Here are some recent quotes from research analysts about Senseonics stock:
- 1. BTIG Research analysts commented, "with Senseonics’ Management Earlier this week, we hosted investor meetings with CEO and CFO York City. Key topics included anticipated FDA approval of the 90-day Eversense CGM, plans for commercialization and reimbursement, and the product pipeline. Management continues to work closely with FDA and remains hopeful that an approval may be secured before the American Diabetes Association scientific sessions in late June. We are optimistic about a potential pre- ADA approval as we feel the FDA likes positive press around large meetings and with a unanimous panel we would be surprised if the agency does not make the approval in time. We highlight other takeaways below." (6/7/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on SENS following the FDA’s scheduling of an advisory committee (adcom panel) meeting to review Senseonics’ Eversense. The meeting is scheduled for Thursday, March 29, and comes just in time to meet management’s guidance for a Q1/18 event. As a reminder, management has guided to a US regulatory approval and commercial launch ~2 months after the adcom panel, positioning the company for a late Q2/18 launch – but we model for first US revenues in the Q3/18. We expect trading activity to increase in coming weeks in anticipation of the event, which we believe will be positive given the strong safety and efficacy data from its pivotal trial. Investment highlights The FDA announced that the Clinical Chemistry and Clinical Toxicology Devices Panel will review and make recommendations on Senseonics’ Eversense PMA submission. The adcom panel is scheduled for Thursday, March 29, 2018 and will be held in Washington DC." (3/2/2018)
- 3. According to Zacks Investment Research, "Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. " (8/15/2017)
Are investors shorting Senseonics?
Senseonics saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 6,313,747 shares, an increase of 21.8% from the May 15th total of 5,184,733 shares. Based on an average daily trading volume, of 630,332 shares, the days-to-cover ratio is currently 10.0 days. Approximately 13.9% of the shares of the stock are sold short.
Who are some of Senseonics' key competitors?
Some companies that are related to Senseonics include MaxCyte (MXCT), Palatin Technologies (PTN), EPIGENOMICS AG/S (EPGNY), Oncimmune (ONC), Profound Medical (PRN), Lexagene (LXG), Sernova (SVA), Co-Diagnostics (CODX), SQI Diagnostics (SQD), Parallax Health Sciences (PRLX), Cambridge Cognition (COG), LED Medical Diagnostics (LMD), 3D Signatures (DXD), GeneNews (GEN) and Oxford Advanced Surfaces Gro (CRON).
Who are Senseonics' key executives?
Senseonics' management team includes the folowing people:
- Dr. Timothy T. Goodnow Ph.D., Chief Exec. Officer, Pres and Director (Age 56)
- Mr. R. Don Elsey MBA, Chief Financial Officer, Sec. and Treasurer (Age 64)
- Dr. E. Lynne Kelley M.D., FACS, Chief Medical Officer (Age 55)
- Dr. Mukul Jain Ph.D., Chief Operating Officer (Age 45)
- Ms. Mirasol G. Panlilio, VP & Gen. Mang. of Global Commercial Operations (Age 53)
Has Senseonics been receiving favorable news coverage?
Media coverage about SENS stock has trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Senseonics earned a media sentiment score of 0.17 on Accern's scale. They also gave media headlines about the company an impact score of 47.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Senseonics' major shareholders?
Senseonics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.01%), Tibra Equities Europe Ltd (0.13%), Element Capital Management LLC (0.07%) and Barclays PLC (0.06%). Company insiders that own Senseonics stock include Douglas A Roeder, Enterprise Associates 10 L New, Mukul Jain and Peter J Barris. View Institutional Ownership Trends for Senseonics.
Which institutional investors are selling Senseonics stock?
SENS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Senseonics company stock in the last year include Douglas A Roeder, Mukul Jain and Peter J Barris. View Insider Buying and Selling for Senseonics.
Which institutional investors are buying Senseonics stock?
How do I buy shares of Senseonics?
Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Senseonics' stock price today?
One share of SENS stock can currently be purchased for approximately $4.71.
How big of a company is Senseonics?
Senseonics has a market capitalization of $434.88 million and generates $330,000.00 in revenue each year. Senseonics employs 58 workers across the globe.
How can I contact Senseonics?
Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The company can be reached via phone at +1-301-5157260.
MarketBeat Community Rating for Senseonics (SENS)
MarketBeat's community ratings are surveys of what our community members think about Senseonics and other stocks. Vote "Outperform" if you believe SENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
